Orbital
The most common orbital tumors in adults — cavernous venous malformation, lymphoma, lacrimal-gland tumors, solitary fibrous tumor, schwannoma, neurofibroma, sphenoid-wing meningioma, and orbital pseudotumor (IOIS).
Medically reviewed by Mark Mazow, MDOculoplastic SurgeonLast updated June 2026
Most orbital tumors in adults are benign and slow-growing. The most common primary orbital tumor is the cavernous venous malformation (the historical “cavernous hemangioma”); the most common orbital malignancy in adults is lymphoma. Age, growth rate, the presence or absence of pain, and the imaging pattern narrow the diagnosis before any biopsy — the entities below are ordered roughly from most to least common.
The most common adult orbital tumors
Not a tumor — compare with
Inflammatory and endocrine disease can mimic an orbital tumor. Compare with orbital pseudotumor (IOIS), IgG4-related orbital disease, and thyroid eye disease — pain, bilateral involvement, or a brisk steroid response point away from a true neoplasm.
← Back to Orbital Tumors overview · Pediatric orbital tumors →
The most common primary orbital tumor in adults. Despite the historical name, it is a venous malformation — a well-encapsulated mass of enlarged vascular spaces within the muscle cone. It typically presents in women in the 4th–5th decade (ages 30–60) with slowly progressive painless axial proptosis. CT shows a well-defined, homogeneously enhancing intraconal mass. MRI demonstrates progressive centripetal enhancement. Treatment is surgical excision when vision is threatened or proptosis is cosmetically significant; asymptomatic lesions can be observed.
Full guide: Cavernous Hemangioma — symptoms, MRI findings, and when to operate →
Solitary fibrous tumor / hemangiopericytoma is a mesenchymal tumor of perivascular cells that can arise anywhere in the orbit. It is less well-encapsulated than cavernous hemangioma and may have locally invasive behavior. Complete surgical excision is the treatment of choice; incomplete excision leads to recurrence. A subset of cases behaves aggressively with distant metastasis. Pathologic grading (WHO) guides adjuvant treatment decisions.
The lacrimal gland, located in the superolateral orbit, gives rise to a spectrum of lesions. The clinical rule of “50/50” applies: approximately 50% of lacrimal gland masses are epithelial neoplasms and 50% are inflammatory or lymphoid. Of the epithelial tumors, 50% are benign mixed tumors (pleomorphic adenoma) and 50% are malignant.
Orbital lymphoma is the most common malignant orbital tumor in adults over 60, accounting for 10–15% of all orbital tumors. Most are B-cell non-Hodgkin lymphomas, predominantly extranodal marginal zone lymphoma (EMZL, also called MALT lymphoma). Orbital and conjunctival lymphoma may be the initial presentation of systemic disease or may arise as a primary ocular adnexal tumor.
Clinical features: Painless, slowly progressive proptosis, lid swelling, or salmon-colored conjunctival mass. The classic imaging finding is a mass that “molds” around orbital structures without bone erosion — reflecting the lymphoma’s soft consistency.
Management: Biopsy followed by systemic staging workup (CT chest/abdomen/pelvis, bone marrow biopsy). Low-grade localized orbital EMZL is treated with low-dose external beam radiation (commonly ~24 Gy) with high local control (often >95%); ultra-low-dose regimens (e.g., 4 Gy) are emerging options for select indolent cases. Systemic or high-grade disease requires chemotherapy (R-CHOP); anti-CD20 therapy (rituximab) is used for B-cell lymphomas.
Orbital neurofibromas may be solitary or plexiform. Plexiform neurofibroma is pathognomonic of Neurofibromatosis type 1 (NF-1) and involves the periorbital and orbital tissues diffusely. It presents in childhood as a “bag of worms” soft tissue mass with S-shaped ptosis and the classic NF-1 “absent greater wing of sphenoid” on imaging (pulsating proptosis due to bony defect). Management is challenging — surgical debulking reduces volume but complete resection is impossible; MEK inhibitor therapy (selumetinib) is now FDA-approved for pediatric plexiform neurofibromas.
Schwannomas arise from the Schwann cells of peripheral nerves and are well-encapsulated, slow-growing tumors. In the orbit, they typically arise from peripheral branches of the trigeminal nerve (CN V) and present as painless, slowly progressive proptosis over years. CT shows a well-defined, enhancing mass. Complete surgical excision is usually curative, though incomplete removal may lead to recurrence; the capsule plane often allows relatively safe dissection, but deep or apical lesions carry a risk of nerve injury.
Meningiomas arising from the sphenoid wing invade the orbit through the superior orbital fissure or directly through bone, producing progressive proptosis, visual loss, and motility restriction. The “en plaque” variant grows as a flat sheet along the bone rather than a discrete mass. CT characteristically shows hyperostosis (bony thickening) of the sphenoid wing — a distinctive feature not seen with orbital lymphoma or metastases.
Management is complex, often requiring multidisciplinary planning with neurosurgery. Surgical decompression is indicated for progressive visual loss; total resection is rarely achievable given the infiltrative growth. Stereotactic radiosurgery (Gamma Knife) provides tumor control for smaller lesions. Observation is appropriate for asymptomatic or slowly progressive disease in older patients.
Orbital pseudotumor — formally termed idiopathic orbital inflammatory syndrome (IOIS) — is a benign, non-specific inflammatory condition of the orbit without identifiable local or systemic cause. It is the most common painful orbital mass in adults and must be distinguished from the tumors described above, as treatment is fundamentally different (anti-inflammatory rather than surgical).
The classic triad: acute painful proptosis + inflammatory eyelid/conjunctival signs + dramatic response to corticosteroids within 24–48 hours. Pain is the key distinguishing feature — most other orbital masses are painless.
MRI with gadolinium is the preferred imaging modality. Laboratory workup excludes systemic causes: CBC, CRP, thyroid function, ACE (sarcoidosis), ANCA (GPA/Wegener’s), ANA, and serum IgG4 (IgG4-related orbital disease). Orbital biopsy is required when the diagnosis is uncertain or when the lesion fails to respond to steroids.
IgG4-ROD is now recognized as a distinct clinicopathological entity separate from idiopathic IOIS. It is characterized by elevated serum IgG4, dense IgG4+ plasma cell infiltration on biopsy, storiform fibrosis, and a tendency to involve multiple organs (pancreas, salivary glands, kidneys). It responds to steroids initially but frequently recurs; rituximab has shown promise for refractory cases.
High-dose oral prednisone (1 mg/kg/day) is first-line. Response within 24–48 hours is characteristic and diagnostically informative — failure to respond should prompt biopsy. Recurrent or steroid-dependent disease is treated with low-dose orbital radiation (20 Gy) or steroid-sparing immunosuppression (methotrexate, mycophenolate, rituximab).
Schedule a consultation with Mark Mazow, MD to learn if this procedure is right for you.